Information Provided By:
Fly News Breaks for June 19, 2015
ZIOP
Jun 19, 2015 | 08:30 EDT
After Ziopharm presented pre-clinical data for its new CAR-T design, BMO Capital says the pre-clinical data for the new design suggest increased persistence, and is likely to translate into increased efficacy. The firm keeps a $15 price target and Outperform rating on the shares.
News For ZIOP From the Last 2 Days
There are no results for your query ZIOP